CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy-Reference-Cited by-同舟云学术

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy

Published:2011-09-10 Issue:14 Volume:25 Page:1747-1751
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Ellis Ronald J.,Badiee Jayraan,Vaida Florin,Letendre Scott,Heaton Robert K.,Clifford David,Collier Ann C.,Gelman Benjamin,McArthur Justin,Morgello Susan,McCutchan J. Allen,Grant Igor

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference8 articles.

1. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients.;Munoz-Moreno;AIDS Res Hum Retroviruses,2008

2. The prevalence and incidence of neurocognitive impairment in the HAART era.;Robertson;AIDS,2007

3. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort.;Tozzi;J Neurovirol,2005

4. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.;Heaton;Neurology,2010

5. Updated research nosology for HIV-associated neurocognitive disorders.;Antinori;Neurology,2007

Cited by 342 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamics of peripheral T cell exhaustion and monocyte subpopulations in neurocognitive impairment and brain atrophy in chronic HIV infection;Journal of NeuroVirology;2024-06-29

2. CD4 nadir and neurocognitive trajectories in people living with HIV;Journal of NeuroVirology;2024-06-10

3. Association between tight junction proteins and cognitive performance in untreated persons with HIV;AIDS;2024-05-02

4. The Impact of Cannabis Use on Cognition in People with HIV: Evidence of Function-Dependent Effects and Mechanisms from Clinical and Preclinical Studies;Current HIV/AIDS Reports;2024-04-11

5. Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial;Journal of the American Heart Association;2024-04-02